Inhaled drug delivery for tuberculosis therapy

Pharmaceutical Research

Volumn 26, Issue 11, 2009, Pages 2401-2416

  Muttil, Pavan ^a   Wang, Chenchen ^a   Hickey, Anthony J ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

Alveolar macrophages; Dendritic cells; Inhalation delivery; Microparticles; Tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOGLYCOSIDE DERIVATIVE; AMINOSALICYLIC ACID; AMPHOTERICIN B; AZTREONAM; CAPREOMYCIN; COLISTIN; CYCLOSERINE; DENUFOSOL; DURAMYCIN; ETHAMBUTOL; ETHIONAMIDE; GAMMA INTERFERON; GENTAMICIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; PACLITAXEL; PENTAMIDINE ISETHIONATE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBAVIRIN; RIFAMPICIN; STREPTOMYCIN; TOBRAMYCIN; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; ZANAMIVIR;

BACTERIAL STRAIN; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG UPTAKE; HUMAN; IN VITRO STUDY; INFLUENZA; LUNG ASPERGILLOSIS; LUNG LESION; MORBIDITY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; TREATMENT OUTCOME; TUBERCULOSIS;

ADMINISTRATION, INHALATION; ANTITUBERCULAR AGENTS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 70350228508     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-009-9957-4     Document Type: Review

References (151)

1. Spiers HH. Tuberculosis or consumption. Ohio; 1906.
2. Daniel TM, Bates JH, Downes KA. History of tuberculosis. In: Bloom BR, editor. Tuberculosis: pathogenesis, protection, and control. Washington: American Society for Microbiology; 1994. p. 13-24.
3. B Gandevia 1975 Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders Postgrad Med J. 51 7 SUPPL 13 20 785420
4. O' Callaghan C, Nerbrink O, Vidgren MT. The history of inhaled drug therapy. In: Bisgaard H, et al., editors. Drug delivery to the lung. New York: Informa Health Care; 2001. p. 1-20.
5. American Thoracic Society, Infectious diseases society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. (2005); 171(4):388-416.
6. F Silveira DL Paterson 2005 Pulmonary fungal infections Curr Opin Pulm Med. 11 3 242 6 15818187
7. GC Wood JM Swanson 2007 Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia Drugs 67 6 903 14 17428107
8. P Borsje JC de Jongste JW Mouton HA Tiddens 2000 Aerosol therapy in cystic fibrosis: a survey of 54 CF centers Pediatr Pulmonol. 30 5 368 76 11064427
9. SW Kim JL Kuti DP Nicolau 2008 Inhaled antimicrobial therapies for respiratory infections Curr Infect Dis Rep. 10 1 29 36 18377812
10. JK Hagerman KE Hancock ME Klepser 2006 Aerosolised antibiotics: a critical appraisal of their use Expert Opin Drug Deliv. 3 1 71 86 16370941
11. ME Klepser 2004 Role of nebulized antibiotics for the treatment of respiratory infections Curr Opin Infect Dis. 17 2 109 12 15021049
12. P Flume ME Klepser 2002 The rationale for aerosolized antibiotics Pharmacotherapy 22 3 Pt 2 71S 9S 11898884
13. Aziz MA. Anti-tuberculosis drug resistance in the world. 2004 World Health Organization, Geneva. 3.
14. Starke JR. Tuberculosis. In: McMillan JA, et al., editors. Oski's pediatrics: principles and practice. Philadelphia: Lippincott Williams and Wilkins; 2006. p. 1142-54.
15. World Health Organization (WHO). Tuberculosis Fact sheet No104-Global and regional incidence. Revised March 2007, Retrieved on 19th March 2009.
16. JL Flynn J Chan 2001 Immunology of tuberculosis Annu Rev Immunol. 19 93 129 11244032
17. GW Comstock 1982 Epidemiology of tuberculosis Am Rev Respir Dis. 125 3 Pt 2 8 15 7073104
18. R Pandey GK Khuller 2005 Antitubercular inhaled therapy: opportunities, progress and challenges J Antimicrob Chemother 55 4 430 5 15761077
19. AJ Wolf B Linas GJ Trevejo-Nunez E Kincaid T Tamura K Takatsu, et al. 2007 Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo J Immunol. 179 4 2509 19 17675513
20. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1376-95.
21. JA Armstrong PD Hart 1971 Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes J Exp Med 134 3 Pt 1 713 40 15776571
22. AP Sinai KA Joiner 1997 Safe haven: the cell biology of nonfusogenic pathogen vacuoles Annu Rev Microbiol. 51 415 62 9343356
23. Haas DW. Mycobacterium tuberculosis. In: Mandell GL, et al., editors. Principles and practice of infectious diseases. Philadelphia: Churchil Livingstone; 2000. p. 2576-607.
24. T Ulrichs SH Kaufmann 2006 New insights into the function of granulomas in human tuberculosis J Pathol 208 2 261 9 16362982
25. Haas DW. Mycobacteria: tuberculosis and leprosy. In: Schaechter M, et al., editors. Schaechter's mechanisms of microbial disease. Baltimore: Lippincott Williams & Wilkins; 2006. p. 251-62.
26. Venable SJ. Drugs treating mycobacterial infections. In: Aschenbrenner DS, Venable SJ, editors. Drug therapy in nursing. Baltimore: Lippincott Williams & Wilkins; 2008. p. 828-41.
27. EL Nuermberger T Yoshimatsu S Tyagi RJ O'Brien AN Vernon RE Chaisson, et al. 2004 Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis Am J Respir Crit Care Med. 169 3 421 6 14578218
28. S Tyagi E Nuermberger T Yoshimatsu K Williams I Rosenthal N Lounis, et al. 2005 Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis Antimicrob Agents Chemother. 49 6 2289 93 15917523
29. AJ Lenaerts V Gruppo KS Marietta CM Johnson DK Driscoll NM Tompkins, et al. 2005 Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models Antimicrob Agents Chemother. 49 6 2294 301 15917524
30. LV Sacks S Pendle D Orlovic M Andre M Popara G Moore, et al. 2001 Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis Clin Infect Dis. 32 1 44 9 11118385
31. JE Conte Jr JA Golden S Duncan E McKenna E Zurlinden 1999 Intrapulmonary concentrations of pyrazinamide Antimicrob Agents Chemother. 43 6 1329 33 10348747
32. JE Conte Jr JA Golden M McQuitty J Kipps S Duncan E McKenna, et al. 2002 Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid Antimicrob Agents Chemother. 46 8 2358 64 12121905
33. Murphy A. Drug delivery to the lungs. In: Murphy A, editor. Asthma in focus. Chicago: Pharmaceutical; 2007. p. 113-32.
34. L Garcia-Contreras J Fiegel MJ Telko K Elbert A Hawi M Thomas, et al. 2007 Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model Antimicrob Agents Chemother. 51 8 2830 6 17517845
35. S Suarez P O'Hara M Kazantseva CE Newcomer R Hopfer DN McMurray, et al. 2001 Airways delivery of rifampicin microparticles for the treatment of tuberculosis J Antimicrob Chemother. 48 3 431 4 11533012
36. L Garcia-Contreras V Sethuraman M Kazantseva V Godfrey AJ Hickey 2006 Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig J Antimicrob Chemother. 58 5 980 6 16971416
37. DA Edwards A Ben-Jebria R Langer 1998 Recent advances in pulmonary drug delivery using large, porous inhaled particles J Appl Physiol. 85 2 379 85 9688708
38. BJ Rijnders JJ Cornelissen L Slobbe MJ Becker JK Doorduijn WC Hop, et al. 2008 Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial Clin Infect Dis. 46 9 1401 1408 18419443
39. GK Khuller M Kapur S Sharma 2004 Liposome technology for drug delivery against mycobacterial infections Curr Pharm Des. 10 26 3263 74 15544514
40. SP Vyas ME Kannan S Jain V Mishra P Singh 2004 Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages Int J Pharm. 269 1 37 49 14698575
41. CE Astete CM Sabliov 2006 Synthesis and characterization of PLGA nanoparticles J Biomater Sci Polym Ed. 17 3 247 89 16689015
42. D Horn J Rieger 2001 Organic nanoparticles in the aqueous phase-theory, experiment, and use Angew Chem Int Ed Engl. 40 23 4330 61 12404417
43. A Sharma S Sharma GK Khuller 2004 Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis J Antimicrob Chemother 54 4 761 6 15329364
44. J Heyder J Gebhart G Rudolf CF Schiller W Stahlhofen 1986 Deposition of particles in the human respiratory tract in the size range 0. 005-15 μm J Aerosol Sci. 17 5 811 25
45. JC Sung BL Pulliam DA Edwards 2007 Nanoparticles for drug delivery to the lungs Trends Biotechnol. 25 12 563 70 17997181
46. L Thiele HP Merkle E Walter 2003 Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages Pharm Res. 20 2 221 8 12636160
47. L Thiele HP Merkle E Walter 2002 Phagocytosis of synthetic particulate vaccine delivery systems to program dendritic cells Expet Rev Vaccine 1 2 215 26
48. Gehr P, Geiser M, Im Hof V, Schurch S. Surfactant: ultrafine particle interactions. In: Brown LM, editor. Ultrafine particles in the atmosphere. London: Imperial college press; 2003. p. 187-202.
49. PG Holt DH Strickland ME Wikstrom FL Jahnsen 2008 Regulation of immunological homeostasis in the respiratory tract Nat Rev Immunol 8 2 142 52 18204469
50. Neutra MR, Kraehenbhul J-P. Cellular and molecular basis for antigen transport across epithelial barriers. In: Mestecky J, et al., editors. Mucosal immunology. New York: Academic; 2005. p. 111-30.
51. R Pandey GK Khuller 2004 Polymer based drug delivery systems for mycobacterial infections Curr Drug Deliv. 1 3 195 201 16305383
52. P O'Hara AJ Hickey 2000 Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization Pharm Res. 17 8 955 61 11028941
53. AH Chow HH Tong P Chattopadhyay BY Shekunov 2007 Particle engineering for pulmonary drug delivery Pharm Res. 24 3 411 37 17245651
54. SP Newman WW Busse 2002 Evolution of dry powder inhaler design, formulation, and performance Respir Med. 96 5 293 304 12113378
55. RJ Malcolmson JK Embleton 1998 Dry powder formulations for pulmonary delivery Pharm Sci Technol Today. 1 394 8
56. K Koushik UB Kompella 2004 Particle and device engineering for inhalation drug delivery Drug Del Technol. 4 40 50
57. CJ Riendeau H Kornfeld 2003 THP-1 cell apoptosis in response to Mycobacterial infection Infect Immun. 71 1 254 9 12496173
58. AB Yadav A Misra 2007 Enhancement of apoptosis of THP-1 cells infected with Mycobacterium tuberculosis by inhalable microparticles and relevance to bactericidal activity Antimicrob Agents Chemother. 51 10 3740 2 17664326
59. RK Verma J Kaur K Kumar AB Yadav A Misra 2008 Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice Antimicrob Agents Chemother. 52 9 3195 201 18591268
60. R Sharma P Muttil AB Yadav SK Rath VK Bajpai U Mani, et al. 2007 Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra J Antimicrob Chemother. 59 3 499 506 17242031
61. C Wang P Muttil D Lu AA Beltran-Torres L Garcia-Contreras AJ Hickey 2009 Screening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines Aaps J. 11 1 139 47 19277872
62. Williams R. Bioequivalence and therapeutic equivalence. In: Welling PG, et al., editors. Pharmaceutical bioequivalence. New York: Marcel Dekker; 1991.
63. JC Sung L Garcia-Contreras JL Verberkmoes CA Peloquin KJ Elbert AJ Hickey, et al. 2009 Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation Antimicrob Agents Chemother. 53 4 1338 43 19139288
64. LH Ly MI Russell DN McMurray 2008 Cytokine profiles in primary and secondary pulmonary granulomas of Guinea pigs with tuberculosis Am J Respir Cell Mol Biol. 38 4 455 62 18032570
65. Demidov SV, Miasnikov VG, Chernushenko EF, Osipova LS. Effect of thymus preparations and anti-tuberculosis agents on immunologic reactivity and the course of the tuberculosis process in experimental animals. Probl Tuberk. 1991;(12):52-4.
66. CM Johnson R Pandey S Sharma GK Khuller RJ Basaraba IM Orme, et al. 2005 Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis Antimicrob Agents Chemother. 49 10 4335 8 16189115
67. JD Ernst 1998 Macrophage receptors for Mycobacterium tuberculosis Infect Immun. 66 4 1277 81 9529042
68. DV Cousins R Bastida A Cataldi V Quse S Redrobe S Dow, et al. 2003 Tuberculosis in seals caused by a novel member of the Mycobacterium tuberculosis complex: Mycobacterium pinnipedii sp. nov Int J Syst Evol Microbiol. 53 Pt 5 1305 14 13130011
69. R Brosch SV Gordon M Marmiesse P Brodin C Buchrieser K Eiglmeier, et al. 2002 A new evolutionary scenario for the Mycobacterium tuberculosis complex Proc Natl Acad Sci U S A. 99 6 3684 9 11891304
70. W Bishai 2001 Tuberculosis transmission-rogue pathogen or rogue patient? Am J Respir Crit Care Med. 164 7 1104 5 11673188
71. SE Valway MP Sanchez TF Shinnick I Orme T Agerton D Hoy, et al. 1998 An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis N Engl J Med. 338 10 633 9 9486991
72. M Zhang J Gong Z Yang B Samten MD Cave PF Barnes 1999 Enhanced capacity of a widespread strain of Mycobacterium tuberculosis to grow in human macrophages J Infect Dis. 179 5 1213 7 10191225
73. Young DB. Strategies for new drug development. In: Bloom BR, editor. Tuberculosis: pathogenesis, protection, and control. Washington: American Society for Microbiology; 1994. p. 559-68.
74. CA Fux M Shirtliff P Stoodley JW Costerton 2005 Can laboratory reference strains mirror "real-world" pathogenesis? Trends Microbiol. 13 2 58 63 15680764
75. S Gagneux PM Small 2007 Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development Lancet Infect Dis. 7 5 328 37 17448936
76. Gagneux S. Strain variation and evolution. In: Parish T, Brown A, editors. Mycobacterium: genomics and molecular biology. Portland: Horizon Scientific; 2009. p. 1-18.
77. DN McMurray FM Collins AM Dannenberg Jr DW Smith 1996 Pathogenesis of experimental tuberculosis in animal models Curr Top Microbiol Immunol. 215 157 79 8791713
78. CA Scanga VP Mohan H Joseph K Yu J Chan JL Flynn 1999 Reactivation of latent tuberculosis: variations on the Cornell murine model Infect Immun. 67 9 4531 8 10456896
79. A Ladefoged K Bunch-Christensen J Guld 1976 Tuberculin sensitivity in guinea-pigs after vaccination with varying doses of BCG of 12 different strains Bull World Health Organ. 53 4 435 43 1086736
80. DN McMurray 2001 Disease model: pulmonary tuberculosis Trends Mol Med. 7 3 135 7 11286786
81. IM Orme 2005 Current progress in tuberculosis vaccine development Vaccine 23 17-18 2105 8 15755579
82. CK Stover P Warrener DR VanDevanter DR Sherman TM Arain MH Langhorne, et al. 2000 A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis Nature 405 6789 962 6 10879539
83. S Suarez P O'Hara M Kazantseva CE Newcomer R Hopfer DN McMurray, et al. 2001 Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model Pharm Res. 18 9 1315 9 11683246
84. McMurray DN. Guinea pig model of tuberculosis. In: Bloom BR, editor. Tuberculosis: pathogenesis, protection, and control. Washington: American Society for Microbiology; 1994. p. 135-147.
85. Turner OC, Basaraba RJ, Frank AA, Orme IM. Granuloma formation in mice and guinea pig models of experimental tuberculosis. In: Boros DL, editor. Granulomatous infections and inflammation: cellular and molecular mechanisms. Washington: ASM; 2003. p. 65-84.
86. DN McMurray 2003 Hematogenous reseeding of the lung in low-dose, aerosol-infected guinea pigs: unique features of the host-pathogen interface in secondary tubercles Tuberculosis (Edinb) 83 1-3 131 4
87. HI Boshoff CE Barry 3rd 2005 Tuberculosis-metabolism and respiration in the absence of growth Nat Rev Microbiol. 3 1 70 80 15608701
88. Dannenberg AM, Rook GAW. Pathogenesis of pulmonary tuberculosis: an interplay of tissue-damaging and macrophage-activating immune responses-dual mechanisms that control bacillary multiplication. In: Bloom BR, editor. Tuberculosis: pathogenesis, protection, and control. Washington: ASM; 1994. p. 459-83.
89. AJ Lenaerts D Hoff S Aly S Ehlers K Andries L Cantarero, et al. 2007 Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910 Antimicrob Agents Chemother. 51 9 3338 45 17517834
90. SH Cho S Warit B Wan CH Hwang GF Pauli SG Franzblau 2007 Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis Antimicrob Agents Chemother. 51 4 1380 5 17210775
91. MC Tsai S Chakravarty G Zhu J Xu K Tanaka C Koch, et al. 2006 Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension Cell Microbiol 8 2 218 32 16441433
92. DW Smith V Balasubramanian E Wiegeshaus 1991 A guinea pig model of experimental airborne tuberculosis for evaluation of the response to chemotherapy: the effect on bacilli in the initial phase of treatment Tubercle 72 3 223 31 1771684
93. RJ Basaraba DD Dailey CT McFarland CA Shanley EE Smith DN McMurray, et al. 2006 Lymphadenitis as a major element of disease in the guinea pig model of tuberculosis Tuberculosis (Edinb) 86 5 386 94
94. RJ Basaraba EE Smith CA Shanley IM Orme 2006 Pulmonary lymphatics are primary sites of Mycobacterium tuberculosis infection in guinea pigs infected by aerosol Infect Immun. 74 9 5397 401 16926435
95. Dannenberg A. Rabbit model of tuberculosis. In: Bloom BR, editor. Tuberculosis: pathogenesis, protection, and control. Washington: American Society for Microbiology; 1994. p. 149-56.
96. DN McMurray 2000 A nonhuman primate model for preclinical testing of new tuberculosis vaccines Clin Infect Dis. 30 Suppl 3 S210 2 10875785
97. WR Barclay WM Busey DW Dalgard RC Good BW Janicki JE Kasik, et al. 1973 Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette-Guerin Am Rev Respir Dis. 107 3 351 8 4632221
98. GP Walsh EV Tan ECD Cruz RM Abalos LG Villahermosa LJ Young, et al. 1996 The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease Nat Med 2 430 6 8597953
99. JM Davis H Clay JL Lewis N Ghori P Herbomel L Ramakrishnan 2002 Real-time visualization of mycobacterium-macrophage interactions leading to initiation of granuloma formation in zebrafish embryos Immunity 17 6 693 702 12479816
100. JL Flynn 2006 Lessons from experimental Mycobacterium tuberculosis infections Microbes Infect. 8 4 1179 88 16513383
101. UD Gupta VM Katoch 2005 Animal models of tuberculosis Tuberculosis (Edinb) 85 5-6 277 93
102. AG Harmsen BA Muggenburg MB Snipes DE Bice 1985 The role of macrophages in particle translocation from lungs to lymph nodes Science 230 4731 1277 80 4071052
103. D Corry P Kulkarni MF Lipscomb 1984 The migration of bronchoalveolar macrophages into hilar lymph nodes Am J Pathol. 115 3 321 8 6731584
104. Tran L, Kuempel E. Biologically based lung dosimetry and exposure-dose response models for poorly soluble inhaled particles. In: Donaldson K, Borm P, editors. Particle toxicology. New York: CRC; 2006. p. 351-86.
105. B Pulendran JL Smith G Caspary K Brasel D Pettit E Maraskovsky, et al. 1999 Distinct dendritic cell subsets differentially regulate the class of immune response in vivo Proc Natl Acad Sci U S A. 96 3 1036 41 9927689
106. S LeibundGut-Landmann O Gross MJ Robinson F Osorio EC Slack SV Tsoni, et al. 2007 Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17 Nat Immunol. 8 6 630 8 17450144
107. JE Conte Jr J Golden S Duncan E McKenna E Lin E Zurlinden 1996 Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects Antimicrob Agents Chemother. 40 7 1617 22 8807050
108. JE Conte Jr JA Golden S Duncan E McKenna E Zurlinden 1995 Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin Antimicrob Agents Chemother. 39 2 334 8 7726492
109. JE Conte Jr JA Golden J Kipps ET Lin E Zurlinden 2001 Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrations Antimicrob Agents Chemother. 45 10 2891 6 11557486
110. JE Conte Jr JA Golden M McQuitty J Kipps ET Lin E Zurlinden 2000 Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects Antimicrob Agents Chemother. 44 4 985 90 10722501
111. GM Cauthen JO Kilburn GD Kelly RC Good 1988 Resistance to antituberculosis drugs in patients with and without prior treatment: survey of 31 state and large city laboratories, 1982-1986 Am Rev Respir Dis. 137 Suppl 260
112. J Hiyama M Marukawa Y Shiota T Ono H Mashiba 2000 Factors influencing response to treatment of pulmonary tuberculosis Acta Med Okayama. 54 4 139 45 10985173
113. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis. 1989;139(4):871-876.
114. Diagnosis and treatment. In: Yancey D, editors. Tuberculosis, Twenty-first century books, Minneapolis; 2007. p. 58-76.
115. Davies PDO, Cooke R. Mycobacterial antimicrobial resistance. In: Fong IW, Drlica K, editors. Antimicrobial resistance and implications for the 21st century. New York: Springer science and Business media; 2007. p. 161-206.
116. EE Telzak BA Fazal CL Pollard GS Turett JE Justman S Blum 1997 Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis Clin Infect Dis. 25 3 666 70 9314458
117. R Condos B Raju A Canova BY Zhao M Weiden WN Rom, et al. 2003 Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients Infect Immun. 71 4 2058 64 12654826
118. R Condos FP Hull NW Schluger WN Rom GC Smaldone 2004 Regional deposition of aerosolized interferon-gamma in pulmonary tuberculosis Chest 125 6 2146 55 15189935
119. Francis C. Nebulizers and Inhalers. In: Francis C, editor. Respiratory care. Oxford: Wiley-Blackwell; 2006. p. 97-124.
120. JD Crapo BE Barry P Gehr M Bachofen ER Weibel 1982 Cell number and cell characteristics of the normal human lung Am Rev Respir Dis. 126 2 332 7 7103258
121. Harkema JR, Plopper CG, Pinkerton KE. Comparative structure of the respiratory tract: airway architecture in humans and animals. In: Cohen MD, et al., editors. Pulmonary immunotoxicology. New York: Springer; 2000. p. 1-60.
122. Edwards DA, Valente AX, Man J, Tsapis N. Recent advances related to the systemic delivery of therapeutic molecules by inhalation. In: Hickey AJ, editor. Pharmaceutical inhalation aerosol technology. New York: Marcel Dekker; 2003. p. 541-50.
123. Dalby RN, Tiano SL, Hickey AJ. Medical devices for the delivery of therapeutic aerosols to the lungs. In: Hickey AJ, editor. Inhalation aerosols: physical and biological basis for therapy. New York: Informa health care; 2006. p. 417-44.
124. JS Patton 1996 Mechanisms of macromolecule absorption by the lungs Adv Drug Deliv Rev. 19 1 3 36
125. LS Schanker 1978 Drug absorption from the lung Biochem Pharmacol. 27 4 381 5 629798
126. JS Patton CS Fishburn JG Weers 2004 The lungs as a portal of entry for systemic drug delivery Proc Am Thorac Soc. 1 4 338 44 16113455
127. JA Hemberger LS Schanker 1979 Postnatal development of carrier-mediated absorption of disodium cromoglycate from the rat lung Proc Soc Exp Biol Med. 161 3 285 8 111264
128. Hickey AJ, Thompson DC. Physiology of the airways. In: Hickey A, editor. Pharmaceutical inhalation aerosol technology. New York: Marcel Dekker; 2003. p. 1-27.
129. JA Golden D Chernoff H Hollander D Feigal JE Conte 1989 Prevention of Pneumocystis carinii pneumonia by inhaled pentamidine Lancet 1 8639 654 7 2564468
130. BW Ramsey MS Pepe JM Quan KL Otto AB Montgomery J Williams-Warren, et al. 1999 Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group N Engl J Med. 340 1 23 30 9878641
131. DE Geller MW Konstan J Smith SB Noonberg C Conrad 2007 Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety Pediatr Pulmonol. 42 4 307 13 17352404
132. B Heinzl E Eber B Oberwaldner G Haas MS Zach 2002 Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study Pediatr Pulmonol. 33 1 32 7 11747258
133. NM Byrne PM Keavey JD Perry FK Gould DA Spencer 2003 Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis Arch Dis Child. 88 8 715 8 12876172
134. RR Deterding LM Lavange JM Engels DW Mathews SJ Coquillette AS Brody, et al. 2007 Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis Am J Respir Crit Care Med. 176 4 362 9 17446337
135. KS McCoy AL Quittner CM Oermann RL Gibson GZ Retsch-Bogart AB Montgomery 2008 Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis Am J Respir Crit Care Med. 178 9 921 8 18658109
136. I Steiner P Errhalt K Kubesch M Hubner M Holy M Bauer, et al. 2008 Pulmonary pharmacokinetics and safety of nebulized duramycin in healthy male volunteers Naunyn Schmiedebergs Arch Pharmacol. 378 3 323 33 18500510
137. Aerosol consensus statement. Consensus Conference on Aerosol Delivery. Chest 1991;100(4):1106-1109.
138. C LaForce CY Man FW Henderson JE McElhaney FC Hampel R Bettis Jr, et al. 2007 Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial Clin Ther. 29 8 1579 90 17919541 discussion 1577-1578
139. M Boeckh J Englund Y Li C Miller A Cross H Fernandez, et al. 2007 Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients Clin Infect Dis. 44 2 245 9 17173225
140. J Fiegel L Garcia-Contreras M Thomas J VerBerkmoes K Elbert A Hickey, et al. 2008 Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin Pharm Res. 25 4 805 11 17657592
141. N Tsapis D Bennett K O'Driscoll K Shea MM Lipp K Fu, et al. 2003 Direct lung delivery of para-aminosalicylic acid by aerosol particles Tuberculosis (Edinb) 83 6 379 85
142. R Sharma D Saxena AK Dwivedi A Misra 2001 Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis Pharm Res. 18 10 1405 10 11697465
143. R Pandey A Sharma A Zahoor S Sharma GK Khuller B Prasad 2003 Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis J Antimicrob Chemother. 52 6 981 6 14613962
144. R Pandey GK Khuller 2005 Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis Tuberculosis (Edinb) 85 4 227 34
145. R Pandey S Sharma GK Khuller 2004 Nebulization of liposome encapsulated antitubercular drugs in guinea pigs Int J Antimicrob Agents. 24 1 93 4 15225870
146. Kurunov Iu N, Ursov IG, Krasnov VA, Petrenko TI, Iakovchenko NN, Svistelnik AV, et al. Effectiveness of liposomal antibacterial drugs in the inhalation therapy of experimental tuberculosis. Probl Tuberk. 1995;(1):38-40.
147. M Takenaga Y Ohta Y Tokura A Hamaguchi R Igarashi A Disratthakit, et al. 2008 Lipid microsphere formulation containing rifampicin targets alveolar macrophages Drug Deliv. 15 3 169 75 18379929
148. A Yoshida M Matumoto H Hshizume Y Oba T Tomishige H Inagawa, et al. 2006 Selective delivery of rifampicin incorporated into poly(DL-lactic-co-glycolic) acid microspheres after phagocytotic uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium bovis Calmette-Guerin Microbes Infect. 8 9-10 2484 91 16879999
149. P Muttil J Kaur K Kumar AB Yadav R Sharma A Misra 2007 Inhalable microparticles containing large payload of anti-tuberculosis drugs Eur J Pharm Sci. 32 2 140 50 17681458
150. Sen H, Jayanthi S, Sinha R, Sharma R, Muttil P. Inhalable biodegradable microparticles for target-specific drug delivery in tuberculosis and a process thereof. U.S.P.A. Publication. Council of Scientific and Industrial Research; Lupin Limited Research Park. India. 2007;11/684,562.
151. JC Sung DJ Padilla L Garcia-Contreras JL Verberkmoes D Durbin CA Peloquin, et al. 2009 Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery Pharm Res. 26 8 1847 55 19407933